BCLI: BrainStorm Cell Therapeutics Company Total Sales
Gross sales revenue for Brainstorm Cell (BCLI) demonstrates a trend where the parameter value equals 0.00. Brainstorm Cell (BCLI) revenues are based on the success of NurOwn therapy for ALS and FDA approval. High costs for testing and production sterility create a significant barrier to entry. However, regulatory complexities regarding drug registration temporarily hinder the formation of a sustainable competitive advantage for the business.
Analytical breakdowns for BrainStorm Cell Therapeutics (BCLI)
- market value and analyst target forecast:
- market capitalization information:
- book capitalization indicators:
- company liabilities and liquidity data:
Total Debt to Equity Ratio Brainstorm Cell|BCLI - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Brainstorm Cell Therapeutics Inc.|BCLI - Company Aggregate Debts|Debt to Book Value Brainstorm Cell Therapeutics Inc.|BCLI - Company Long-Term Debts|Short-Term Debt BrainStorm Cell Therapeutics|Quick Liquidity brainstorm-cell.com
- business earnings and investment ratios data:
BCLI - Company Net Income|Expected Profit Brainstorm Cell|BCLI - P/E Multiple|Future Price to Earnings brainstorm-cell.com|BCLI - PEG Multiple|Enterprise Value to EBITDA Ratio Brainstorm Cell Therapeutics Inc.|BCLI - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months BrainStorm Cell Therapeutics|BCLI - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months brainstorm-cell.com|BCLI - Earnings per share growth in current year|Projected earnings per share growth rate for next year Brainstorm Cell
- sales volume and revenue indicators:
Summary company analysis:BCLI BrainStorm Cell Therapeutics Inc.
The daily sales chart for Brainstorm Cell (BCLI) filters out market noise, accurately capturing revenue inflows from product sales and allowing investors to identify long-term expansion trends or the risk of asset overvaluation. For Brainstorm Cell (BCLI), this sales trend reflects the commercial success of implementing patented cellular technologies amidst stringent FDA regulation and the high cost of clinical trials.
Key competitors
Biogen Idec (BIIB) - Company Gross Revenue|Company Sales NBIX (Neurocrine Biosciences)|Company Total Sales RGC|Company Revenue Axsome Therapeutics, Inc. AXSM|ACADIA Pharma (ACAD) - Company Total Revenue|XENE - Company Revenue|Company Sales Revenue VKTX (Viking Therapeutics Corp)|Supernus Pharmaceuticals (SUPN) - Company Revenue|Company Sales catalystpharma.com|Company Sales DNLI|HRMY: Company Sales Revenue|Revenue and Sales Volume BHVN|Company Sales Amylyx Corp AMLX|Revenue and Sales Volume TRVI (Trevi Therapeutics)|praxismedicines.com (PRAX) - Company Total Revenue|AVXL - Company Revenue|CBLL: Company Revenue|Prothena Corporation PLC (PRTA) - Company Revenue|ALEC (Alector) - Company Revenue|ANNX (Annexon, Inc.) - Revenue and Sales Volume|Company Revenue OMER|Revenue and Sales Volume NGNE|Company Sales AC Immune S.A. ACIU|Company Revenue Voyager Pharma VYGR|Neumora Corp - Company Revenue|Scilex Holding Company - Revenue and Sales Volume|Company Gross Revenue tevogen.com TVGN|alphacognition.com (ACOG) - Company Revenue|Company Sales Volume CGTX|IKT (Inhibikase) - Revenue and Sales Volume|Company Total Revenue Cassava Pharma SAVA|Company Sales ASRT (Assertio Holdings, Inc.)|Revenue and Sales Volume coyatherapeutics.com (COYA)|Company Revenue Vistagen VTGN|Company Sales Revenue OVID|ABOS - Company Revenue|Company Total Revenue CervoMed Corporation|ATHE: Revenue and Sales Volume|CLNN (Clene) - Company Revenue|Company Revenue PepGen Inc|JUNS: Company Sales Revenue|Revenue and Sales Volume RLMD|Revenue and Sales Volume Annovis Bio Corporation (ANVS)|Revenue and Sales Volume GRCE (Grace Therapeutics)|Company Gross Revenue fireflyneuro.com (AIFF)|KLTO - Company Revenue|NRSN (NeuroSense Therapeutics) - Company Sales Volume|Reviva Pharmaceuticals Holdings (RVPH) - Company Revenue|MTVA - Company Gross Revenue|Company Sales NRXS|HSDT (Helius Medical Technologies Inc.) - Company Total Sales|Company Revenue Passage Bio, Inc. (PASG)|NEUP - Company Total Revenue|Company Revenue Minerva Neurosciences Corp NERV|Company Sales Revenue ATHA|ADXN - Company Revenue|Alzamend Neuro, Inc. (ALZN) - Company Sales|CYCN (cyclerion.com) - Company Sales|Protagenic Therapeutics, Inc. - Company Sales Revenue|KTTA (Pasithea Therapeutics Corp) - Revenue and Sales Volume|Company Sales Cortigent Medical (CRGT)|Revenue and Sales Volume ATXI|CARA - Company Total Revenue|Company Revenue Chromocell Therapeutics Corp. CHRO|Eliem Therapeutics, Inc. - Company Revenue|ITCI - Company Revenue|LBPH: Company Revenue|MRNS: Revenue and Sales Volume|NKGN (nkgenbiotech.com) - Company Revenue|NRBO (NeuroBo Pharmaceuticals, Inc.) - Revenue and Sales Volume|Company Sales Sage Therapeutics Inc. (SAGE)|Company Revenue Neurotrope (SNPX)|Company Revenue TRVN (Trevena Inc)|Revenue and Sales Volume VIGL (Vigil Neuroscience, Inc.)|Company Gross Revenue Anew Medical Inc. (WENA)|CERE - Company Revenue
